Hikma launches $250m buyback with first £1.2m share purchase

Hikma Pharmaceuticals ( (GB:HIK) ) has provided an update.

Hikma Pharmaceuticals has begun executing a $250 million share repurchase programme, buying back 87,500 ordinary shares on 26 February 2026 through Citigroup Global Markets at a volume-weighted average price of 1,394.36 pence. The company plans to cancel these shares, signalling confidence in its valuation and returning excess capital to shareholders.

After this transaction, Hikma holds 12,833,233 shares in treasury and has 234,632,186 ordinary shares in issue, setting the current total voting rights at that level. The buyback and intended cancellation will gradually reduce the free float and may enhance earnings per share, with implications for the stock’s liquidity and ownership structure.

The most recent analyst rating on (GB:HIK) stock is a Buy with a £2300.00 price target. To see the full list of analyst forecasts on Hikma Pharmaceuticals stock, see the GB:HIK Stock Forecast page.

Spark’s Take on GB:HIK Stock

According to Spark, TipRanks’ AI Analyst, GB:HIK is a Outperform.

Hikma Pharmaceuticals’ overall stock score is driven by strong financial performance and attractive valuation. While technical indicators suggest a bearish trend, the company’s strategic achievements and executive confidence provide a positive outlook. Earnings call insights and corporate events further support the stock’s potential for growth.

To see Spark’s full report on GB:HIK stock, click here.

More about Hikma Pharmaceuticals

Hikma Pharmaceuticals is a multinational drug manufacturer listed in London and on Nasdaq Dubai, focusing on generic and specialty pharmaceuticals. The company supplies injectable and oral medicines to global markets, with a particular strength in hospital and emerging-market therapies.

Average Trading Volume: 737,137

Technical Sentiment Signal: Hold

Current Market Cap: £3.64B

For detailed information about HIK stock, go to TipRanks’ Stock Analysis page.